logo
  Join        Login             Stock Quote

Ironwood (IRWD): Constella Approved In Europe To Treat Irritable Bowel Syndrome With Constipation

 November 28, 2012 07:52 AM


(By Balaseshan) Ironwood Pharmaceuticals Inc. (NASDAQ: IRWD) and Almirall S.A. say Constella (linaclotide 290mcg) was approved in Europe to treat Irritable Bowel Syndrome with Constipation (IBS-C) in adults.

The European Commission has granted marketing authorization to Constella (linaclotide 290mcg). This approval follows the positive recommendation received from the European Committee for Medicinal Products for Human Use (CHMP) in September. Almirall expects to begin launching Constella in Europe in the first half of 2013.

"Linaclotide was discovered by Ironwood scientists, and obtaining marketing authorization for Constella in Europe is important progress towards our goal of translating knowledge into medicines that make a difference for patients," said Peter Hecht, Chief Executive of Ironwood.

[Related -Stock Upgrades And Downgrades: CCL, DF, FB, FSLR, IRWD, QLIK, SPWR]

Constella is an oral, once-daily medication. Linaclotide, the active ingredient in Constella®, is a guanylate cyclase-C agonist (GCCA) with visceral analgesic and secretory activities, as stated in the product label for European use.

In non-clinical studies, linaclotide has been shown to reduce visceral pain by decreasing pain-fiber activity and to accelerate gastrointestinal transit by increasing intestinal fluid secretion. Linaclotide acts locally in the intestine with minimal systemic exposure.

"We look forward to continuing to work closely with our partner Almirall in their efforts to bring Constella to adult IBS-C patients in Europe, and we will continue collaborating with our global network of partners with the goal of bringing this medicine to appropriate patients worldwide," said Peter Hecht.

[Related -Stock Upgrades And Downgrades: ADT, CLF, DG, EXC, EGO, IRWD, PCAR]

In April 2009, Almirall signed a license agreement with Ironwood, under which Almirall holds exclusive marketing rights for linaclotide in all European Union member states, plus Russia, the CIS (Commonwealth of Independent States of the former USSR), Switzerland, Norway and Turkey, as well as other countries in Europe, including the countries of former Yugoslavia.

In September 2012, Almirall also signed an agreement by which Forest Laboratories sublicensed its commercialization rights for linaclotide in Mexico to Almirall.

IBS is a functional gastrointestinal disorder impacting over 10% of the European population, and it is estimated that one-third of IBS patients suffer from IBS-C1, which means that approximately 15 million adults across the European Union might be affected.

Symptoms associated with IBS-C include abdominal pain and discomfort, bloating, and constipation resulting in a significant impact on affected individuals. There are few prescription treatment options for this condition approved in the European Union.

IRWD closed Tuesday's regular session down 2.04% at $10.79. The stock has been trading between $10.02 and $15.92 for the past 52 weeks.

iOnTheMarket Premium
Advertisement

Advertisement


Post Comment -- Login is required to post message
Name:  
Alert for new comments:
Your email:
Your Website:
Title:
Comments:
 

rss feed

Latest Stories

article imageInitial Jobless Claims Rose Unexpectedly

Claims unexpectedly rose in the latest report through last weekend to breach 300,000 for the first time read on...

article imageAll Quiet on the Record High Front

What can we glean from the media’s lack of attention to the market’s recent record read on...

article imageThe Chip Maker Short Sellers Should Be Watching

Investing in semiconductor stocks is always tricky. Industry cycles can lead to bumps in the road for the read on...

article imageChicago Fed: US Economic Growth Slowed In October

The pace of US growth slowed more than expected in October, according to this morning’s update of the read on...

Advertisement
Popular Articles

Advertisement
Daily Sector Scan
Partner Center



Fundamental data is provided by Zacks Investment Research, and Commentary, news and Press Releases provided by YellowBrix and Quotemedia.
All information provided "as is" for informational purposes only, not intended for trading purposes or advice. iStockAnalyst.com is not an investment adviser and does not provide, endorse or review any information or data contained herein.
The blog articles are opinions by respective blogger. By using this site you are agreeing to terms and conditions posted on respective bloggers' website.
The postings/comments on the site may or may not be from reliable sources. Neither iStockAnalyst nor any of its independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. You are solely responsible for the investment decisions made by you and the consequences resulting therefrom. By accessing the iStockAnalyst.com site, you agree not to redistribute the information found therein.
The sector scan is based on 15-30 minutes delayed data. The Pattern scan is based on EOD data.